Rieken, Stefan

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Maag, Teresa Esther"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Donath, Sandra"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Knaus, Olga"],["dc.contributor.author","Nauck, Friedemann"],["dc.contributor.author","Overbeck, Tobias Raphael"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2022-06-01T09:39:22Z"],["dc.date.available","2022-06-01T09:39:22Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Purpose Superior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive disease. Despite several publications, recent data concerning symptom relief and oncological outcome as well as potential confounders in treatment response are still scarce. Methods We performed a retrospective single-center analysis of patients receiving urgent RT between 2000 and 2021 at the University Medical Center Göttingen. Symptom relief was evaluated by CTCAE score during the RT course. Effects of variables on symptom relief were assessed by logistic regression. The impact of parameters on overall survival (OS) was evaluated using Kaplan–Meier plot along with the log-rank test and by Cox regression analyses. Statistically significant ( p -value < 0.05) confounders were tested in multivariable analyses. Results A total of 79 patients were included. Symptom relief was achieved in 68.4%. Mean OS was 59 days, 7.6% ( n  = 6) of patients showed long-term survival (> 2 years). Applied RT dose > 39 Gy, clinical target volume (CTV) size < 387 ml, concomitant chemotherapy, and completion of the prescribed RT course were found to be statistically significant for OS; applied RT dose and completion of the prescribed RT course were found to be statistically significant for symptom relief. Conclusion Symptom relief by urgent RT for SVCS was achieved in the majority of patients. RT dose and completion of the RT course were documented as predictors for OS and symptom relief, CTV < 387 ml and concomitant chemotherapy were predictive for OS."],["dc.identifier.doi","10.1007/s00066-022-01952-z"],["dc.identifier.pii","1952"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108456"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome"],["dc.title.alternative","A single-center retrospective analysis of 21 years’ practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1080"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Oncology"],["dc.bibliographiccitation.lastpage","1092"],["dc.bibliographiccitation.volume","29"],["dc.contributor.affiliation","Habermann, Felix-Nikolai Oschinka Jegor; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schmitt, Daniela; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Failing, Thomas; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Jann; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Ziegler, David Alexander; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Laura Anna; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Alt, Niklas Josua; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Muster, Julian; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Donath, Sandra; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Hille, Andrea; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schirmer, Markus Anton; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Guhlich, Manuel; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Rieken, Stefan; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Leu, Martin; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Dröge, Leif Hendrik; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.author","Habermann, Felix-Nikolai Oschinka Jegor"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Failing, Thomas"],["dc.contributor.author","Fischer, Jann"],["dc.contributor.author","Ziegler, David Alexander"],["dc.contributor.author","Fischer, Laura Anna"],["dc.contributor.author","Alt, Niklas Josua"],["dc.contributor.author","Muster, Julian"],["dc.contributor.author","Donath, Sandra"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2022-04-01T10:00:26Z"],["dc.date.available","2022-04-01T10:00:26Z"],["dc.date.issued","2022"],["dc.date.updated","2022-09-03T12:11:44Z"],["dc.description.abstract","The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the influence of diagnostic assessment on outcomes. A total of 96 patients with stereotactic body radiation therapy (SBRT) for NSCLC were included. The number of patients increased from mean 0.9 (2012–2019) to 1.45 per month in the COVID era (p < 0.05). Pandemic-related factors (contact reduction, limited intensive care unit resources) might have influenced clinical decision making towards SBRT. The time from pretreatment assessment (multidisciplinary tumor board decision, bronchoscopy, planning CT) to SBRT was longer during the COVID period (p < 0.05). Reduced services, staff shortage, or appointment management to mitigate infection risks might explain this finding. Overall survival, progression-free survival, locoregional progression-free survival, and distant progression-free survival were superior in patients who received a PET/CT scan prior to SBRT (p < 0.05). This supports that SBRT guidelines advocate the acquisition of a PET/CT scan. A longer time from PET/CT scan/conventional staging to SBRT (<10 vs. ≥10 weeks) was associated with worse locoregional control (p < 0.05). The postponement of diagnostic or therapeutic measures in the pandemic should be discussed cautiously. Patient- and tumor-related features should be evaluated in detail."],["dc.identifier.doi","10.3390/curroncol29020092"],["dc.identifier.pii","curroncol29020092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105426"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1718-7729"],["dc.rights","CC BY 4.0"],["dc.title","Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5585"],["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.editor","Urbanucci, Alfonso"],["dc.date.accessioned","2022-01-11T14:07:50Z"],["dc.date.available","2022-01-11T14:07:50Z"],["dc.date.issued","2021"],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.identifier.doi","10.3390/cancers13215585"],["dc.identifier.pii","cancers13215585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97876"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFB1 and TGFBR1"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3613"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.date.accessioned","2021-04-14T08:27:10Z"],["dc.date.available","2021-04-14T08:27:10Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12123613"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82194"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Evaluation of Prognosticators and Treatment-Related Side Effects in Patients Irradiated Postoperatively for Endometrial Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]